In the present study, beneficial effect of S-
allyl cysteine (SAC) was evaluated in the
lipopolysaccharide/d-
galactosamine (LPS/d-Gal) model of acute liver injury (ALI). To mimic ALI, LPS and d-Gal (50 μg/kg and 400 mg/kg, respectively) were intraperitoneally administered and animals received SAC per os (25 or 100 mg/kg/d) for 3 days till 1 hour before LPS/d-Gal injection. Pretreatment of LPS/d-Gal group with SAC-lowered activities of
alkaline phosphatase,
alanine aminotransferase, and
aspartate aminotransferase and partially reversed inappropriate alterations of hepatic oxidative stress- and
inflammation-related
biomarkers including liver
reactive oxygen species,
malondialdehyde, and hepatic activity of the defensive
enzyme superoxide dismutase, ferric reducing
antioxidant power (FRAP), toll-like receptor-4 (TLR4),
cyclooxygenase 2, NLR family pyrin domain containing 3 (NLRP3),
caspase 1, nuclear factor κB (NF-κB),
interleukin 1β (IL-1β),
IL-6,
tumor necrosis factor-α, and
myeloperoxidase activity. Additionally, SAC was capable to ameliorate apoptotic
biomarkers including
caspase 3 and DNA fragmentation. In summary, SAC can protect liver against LPS/d-Gal by attenuation of neutrophil infiltration, oxidative stress,
inflammation, apoptosis, and pyroptosis which is partly linked to its suppression of TLR4/NF-κB/NLRP3 signaling.